<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045721</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000257268</org_study_id>
    <secondary_id>PBTC-009</secondary_id>
    <nct_id>NCT00045721</nct_id>
  </id_info>
  <brief_title>Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma</brief_title>
  <official_title>Phase I Trial of GLIADEL and O(6)-Benzylguanine in Pediatric Patients With Recurrent Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Chemotherapy placed into the surrounding tissue after surgery to&#xD;
      remove the tumor may kill any remaining tumor cells. O(6)-benzylguanine may increase the&#xD;
      effectiveness of carmustine by making tumor cells more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the safety of combining O(6)-benzylguanine with carmustine&#xD;
      implants in treating children who have recurrent malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose of O(6)-benzylguanine that reliably inhibits alkylguanine-DNA&#xD;
           alkyltransferase activity in pediatric patients with recurrent malignant glioma.&#xD;
&#xD;
        -  Describe the toxic effects of O(6)-benzylguanine with carmustine implant (Gliadel) in&#xD;
           these patients.&#xD;
&#xD;
        -  Investigate antitumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Characterize the pharmacokinetics of O(6)-benzylguanine when administered continuously&#xD;
           over a 9-day period.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of O(6)-benzylguanine.&#xD;
&#xD;
      Patients receive O(6)-benzylguanine (O6-BG) IV over 1 hour immediately followed by O6-BG IV&#xD;
      continuously for 9 days. Two days after initiation of continuous infusion of O6-BG, patients&#xD;
      undergo maximal tumor debulking. At the time of surgery, patients receive up to 8&#xD;
      polifeprosan 20 wafers with carmustine (Gliadel) implanted into the resection cavity.&#xD;
&#xD;
      Cohorts of up to 14 patients receive escalating doses of continuous infusion O6-BG until the&#xD;
      optimally biologically effective dose (BED) is determined. The BED is defined as the dose at&#xD;
      which at least 11 of 14 patients meet the target of complete suppression of alkylguanine-DNA&#xD;
      alkyltransferase levels.&#xD;
&#xD;
      Patients are followed at day 11, at weeks 2, 4, 6, 8, and 12, at months 6, 9, and 12, every 6&#xD;
      months for 4 years, and then annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Biologically effective dose of O(6)-benzylguanine administered continuously in pediatric patients with recurrent malignant glioma</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities associated with the administration of O(6)-benzylguanine and carmustine implants.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
  </secondary_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-benzylguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polifeprosan 20 with carmustine implant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed progressive supratentorial anaplastic astrocytoma or&#xD;
             glioblastoma multiforme&#xD;
&#xD;
          -  No multifocal disease or leptomeningeal dissemination of tumor&#xD;
&#xD;
          -  No evidence of tumor crossing midline&#xD;
&#xD;
          -  Limited intraventricular involvement&#xD;
&#xD;
          -  Measurable unilateral mass at least 10 mm by contrast-enhanced MRI&#xD;
&#xD;
          -  Received prior involved-field radiotherapy as a component of prior therapy&#xD;
&#xD;
          -  Amenable to and in need of significant debulking&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  3 to 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100% OR&#xD;
&#xD;
          -  Lansky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm3*&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3*&#xD;
&#xD;
          -  Hemoglobin greater than 8 g/dL (transfusions allowed) NOTE: * Transfusion independent&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  AST and ALT less than 3 times normal&#xD;
&#xD;
          -  Albumin at least 2 g/dL&#xD;
&#xD;
          -  No overt hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance no greater than 1.5 times normal OR&#xD;
&#xD;
          -  Glomerular filtration rate greater than 70 mL/min&#xD;
&#xD;
          -  No overt renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No overt cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No overt pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Neurological deficits must be stable for at least the past week&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known hypersensitivity to nitrosoureas or polyethylene glycol&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 6 months since prior bone marrow transplantation&#xD;
&#xD;
          -  More than 2 weeks since prior colony-stimulating growth factors (e.g., filgrastim&#xD;
             (G-CSF), sargramostim (GM-CSF), or epoetin alfa)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 2 prior cytotoxic chemotherapy regimens&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens total&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  Prior systemic carmustine (or other nitrosourea) allowed provided patient did not&#xD;
             experience non-hematopoietic grade III/IV toxicity&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent dexamethasone allowed if on a stable dose for at least the past week&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior radiotherapy&#xD;
&#xD;
          -  No prior craniospinal irradiation for metastatic disease&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior biopsy or cytoreductive surgery allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent anticonvulsants allowed&#xD;
&#xD;
          -  No other concurrent anticancer or investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian F. Pollack, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0372</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>James M. Boyett/PBTC Operations and Biostatistics Center Executive Director</name_title>
    <organization>Pediatric Brain Tumor Consortium</organization>
  </responsible_party>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

